[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-001", "question": "A 16-year-old male presents with recurrent stroke-like episodes, mitochondrial myopathy, and lactic acidosis. Muscle biopsy reveals 38% heteroplasmy for the m.3243A>G mutation. Based on current mitochondrial disease criteria, what is the significance of this heteroplasmy level?", "options": ["Insufficient for MELAS diagnosis; >60% required in muscle", "Diagnostic of MELAS; clinical correlation unnecessary", "Above the threshold for clinical expression; supports diagnosis with compatible phenotype", "Only significant if confirmed in blood at >20%", "Requires repeat biopsy; sampling error likely"], "answer": "C", "answer_index": 2, "explanation": "In MELAS, >40% heteroplasmy in muscle correlates with clinical manifestation, but levels of 30-40% with typical phenotype are considered diagnostic. Blood heteroplasmy is less sensitive and declines with age. The threshold concept is critical for interpreting borderline results.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Let me analyze this question about mitochondrial disease and heteroplasmy levels.\n\nThe patient presents with:\n- Recurrent stroke-like episodes\n- Mitochondrial myopathy\n- Lactic acidosis\n\nThese are classic features of MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes).\n\nThe m.3243A>G mutation is the most common mutation associated with MELAS, found in approximately 80% of cases.\n\nRegarding heteroplasmy thresholds:\n- The threshold for clinical expression of the m.3243A>G mutation varies by tissue\n- In muscle, heteroplasmy levels typically need to be above 20-30% for clinical manifestations\n- Blood levels tend to decrease with age due to selection against mutant mtDNA in rapidly dividing cells\n- Muscle is a better tissue for detection as heteroplasmy levels are generally higher and more stable\n\nAnalyzing the options:\nA. \"Insufficient for MELAS diagnosis; >60% required in muscle\" - This is incorrect. There is no strict 60% threshold requirement.\n\nB. \"Diagnostic of MELAS; clinical correlation unnecessary\" - This is incorrect. Mitochondrial disease diagnosis always requires clinical correlation; genetic findings alone are not sufficient.\n\nC. \"Above the threshold for clinical expression; supports diagnosis with compatible phenotype\" - This is correct. 38% heteroplasmy in muscle is above the typical threshold for clinical expression (~20-30%), and with a compatible clinical phenotype (stroke-like episodes, myopathy, lactic acidosis), this supports the diagnosis.\n\nD. \"Only significant if confirmed in blood at >20%\" - This is incorrect. Muscle biopsy findings are actually more reliable than blood for this mutation.\n\nE. \"Requires repeat biopsy; sampling error likely\" - This is incorrect. 38% is a significant level and doesn't suggest sampling error.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-002", "question": "A 19-year-old asymptomatic athlete has a QTc of 315ms on pre-participation screening. Family history reveals sudden cardiac death in a paternal uncle. Genetic testing identifies a gain-of-function KCNH2 mutation (c.1764G>C). According to 2022 ESC guidelines for SQTS, what is the recommended management?", "options": ["No therapy; restriction from competitive sports", "Implantable cardioverter-defibrillator regardless of symptoms", "Quinidine 600mg daily to maintain QTc >360ms", "Flecainide 100mg twice daily for rhythm stabilization", "Annual Holter monitoring without pharmacotherapy"], "answer": "C", "answer_index": 2, "explanation": "For asymptomatic SQTS patients with pathogenic KCNH2 mutations, quinidine is recommended to prolong QT interval and reduce arrhythmia risk. ICD is reserved for symptomatic patients or those with aborted SCD. Flecainide is contraindicated in SQTS.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "I need to analyze this case of Short QT Syndrome (SQTS) based on the 2022 ESC guidelines.\n\nKey findings:\n- 19-year-old asymptomatic athlete\n- QTc = 315ms (very short, <340ms is diagnostic criterion)\n- Family history of sudden cardiac death (SCD) in paternal uncle\n- Genetic testing positive: gain-of-function KCNH2 mutation (this is SQT1)\n\nAccording to 2022 ESC guidelines for SQTS:\n\nICD recommendations:\n- ICD is recommended (Class I) for SQTS patients who have survived cardiac arrest or documented sustained VT\n- ICD should be considered (Class IIa) in SQTS patients with:\n  - Syncope of arrhythmic origin\n  - QTc ≤320ms\n  - Family history of SCD\n\nQuinidine recommendations:\n- Quinidine should be considered (Class IIa) in SQTS patients who:\n  - Qualify for ICD but have contraindication or refuse\n  - Have documented VT/VF and ICD\n  - Are asymptomatic with family history of SCD\n\nIn this case:\n- QTc is 315ms (≤320ms) - this alone is a risk factor\n- Family history of SCD is present\n- Pathogenic mutation confirmed\n\nThe patient has multiple risk factors (QTc ≤320ms AND family history of SCD). According to ESC 2022 guidelines, an ICD should be considered (Class IIa) for asymptomatic patients with QTc ≤320ms or family history of SCD.\n\nHowever, looking at the options:\n- Option B states \"ICD regardless of symptoms\" - this aligns with the guideline that in high-risk asymptomatic patients (very short QTc + family history + pathogenic mutation), ICD is recommended\n- Option C mentions quinidine, which is an alternative but typically for those who refuse/can't have ICD\n\nGiven the combination of:\n1. Very short QTc (315ms, ≤320ms)\n2. Family history of SCD\n3. Confirmed pathogenic mutation\n\nThe ESC 2022 guidelines would support ICD implantation as the primary recommendation for this high-risk profile, even in an asymptomatic patient.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-003", "question": "A 62-year-old woman with Graves disease presents in thyroid storm (Burch-Wartofsky score 65) with pulmonary edema and cardiogenic shock (LVEF 15%, CI 1.8 L/min/m²). She cannot tolerate beta-blockers due to severe decompensation. Which vasoactive agent is most appropriate initial therapy?", "options": ["Norepinephrine for vasopressor support", "Dobutamine for inotropic effect", "Milrinone 0.5 mcg/kg/min for inodilation", "Levosimendan 0.1 mcg/kg/min calcium sensitizer", "Dopamine 10 mcg/kg/min for combined effect"], "answer": "C", "answer_index": 2, "explanation": "In thyroid storm with cardiogenic shock, beta-blockers are contraindicated. Milrinone provides inotropy via phosphodiesterase inhibition independent of beta-adrenergic receptors and offers vasodilation to reduce afterload. Levosimendan is less preferred due to limited data and potential arrhythmogenicity.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Let me analyze this complex case systematically.\n\nPatient Profile:\n- 62-year-old woman with Graves disease\n- Thyroid storm (Burch-Wartofsky score 65 - severe)\n- Pulmonary edema\n- Cardiogenic shock (LVEF 15%, CI 1.8 L/min/m²)\n- Cannot tolerate beta-blockers\n\nKey Considerations:\n\n1. Thyroid storm pathophysiology: Causes hyperdynamic state with increased catecholamine sensitivity, tachycardia, and can lead to high-output heart failure initially, but can progress to low-output failure with severe myocardial dysfunction.\n\n2. Current hemodynamic state: Very low LVEF (15%) and low cardiac index (1.8) indicate severe cardiogenic shock with pump failure.\n\n3. Beta-blocker intolerance: This is critical - rules out agents that might worsen decompensation.\n\nAnalyzing each option:\n\nA. Norepinephrine: Primarily a vasopressor with alpha-1 effects. In cardiogenic shock with low CI, pure vasoconstriction could increase afterload and worsen cardiac output. However, it does have some beta-1 effects.\n\nB. Dobutamine: Beta-1 agonist providing inotropy. However, in thyroid storm, there's already increased catecholamine sensitivity. Dobutamine could worsen tachycardia and increase myocardial oxygen demand, potentially dangerous in this setting.\n\nC. Milrinone: PDE-3 inhibitor - provides inotropy AND vasodilation (inodilator). Works independently of beta-receptors. Would improve contractility while reducing afterload (beneficial in pulmonary edema). Doesn't increase catecholamine sensitivity issues.\n\nD. Levosimendan: Calcium sensitizer with vasodilatory properties. Good inotrope that doesn't increase oxygen demand significantly. However, may cause significant hypotension, and in acute cardiogenic shock, milrinone is more commonly used and better studied.\n\nE. Dopamine 10 mcg/kg/min: At this dose, has significant beta and alpha effects. Would increase heart rate and could worsen the hyperdynamic/tachycardic state in thyroid storm.\n\nBest Choice:\nMilrinone is ideal because:\n- Works independently of beta-adrenergic receptors (important given catecholamine hypersensitivity in thyroid storm)\n- Provides both inotropy and afterload reduction\n- Helps with pulmonary edema through vasodilation\n- Less likely to cause tachycardia compared to catecholamines\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-004", "question": "A 6-year-old boy presents with recurrent lacunar strokes, livedo racemosa, and systemic vasculitis. ADA2 enzyme activity is <5% of normal. Genetic testing confirms biallelic loss-of-function ADA2 mutations. What is the first-line therapy for preventing further cerebrovascular events?", "options": ["High-dose prednisone with cyclophosphamide induction", "Rituximab 750mg/m² every 4 weeks", "Etanercept 0.8mg/kg weekly subcutaneously", "Anakinra 2mg/kg daily subcutaneously", "Aspirin 5mg/kg daily antiplatelet therapy"], "answer": "C", "answer_index": 2, "explanation": "DADA2 is a monogenic interferonopathy where TNF-α drives vasculitic manifestations. TNF inhibition with etanercept prevents stroke recurrence and treats systemic vasculitis, while traditional immunosuppressants are ineffective. IL-1 blockade is second-line.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This question describes a classic presentation of Deficiency of Adenosine Deaminase 2 (DADA2), which is characterized by:\n- Recurrent lacunar strokes (especially in children)\n- Livedo racemosa\n- Systemic vasculitis\n- Very low ADA2 enzyme activity\n- Biallelic loss-of-function mutations in ADA2 gene\n\nFor DADA2, the treatment approach is well-established:\n\nOption A (High-dose prednisone with cyclophosphamide): While this might be used for other vasculitides, it is not the first-line treatment for DADA2 and doesn't address the underlying pathophysiology effectively.\n\nOption B (Rituximab): This is a B-cell depleting agent used for some autoimmune conditions but is not first-line for DADA2.\n\nOption C (Etanercept - TNF inhibitor): This is the correct answer. TNF inhibitors, particularly etanercept, have been shown to be highly effective in DADA2. They dramatically reduce stroke risk and control the vasculitis. The mechanism relates to the fact that ADA2 deficiency leads to increased TNF production and macrophage activation, making TNF blockade the targeted therapy of choice.\n\nOption D (Anakinra - IL-1 inhibitor): This is used for other autoinflammatory conditions but is not the standard treatment for DADA2.\n\nOption E (Aspirin): While antiplatelet therapy might seem logical for stroke prevention, it does not address the underlying inflammatory vasculopathy and is not sufficient as monotherapy.\n\nTNF inhibitors (etanercept or adalimumab) are the established first-line therapy for DADA2 to prevent strokes and control vasculitis.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-005", "question": "A 30-year-old G2P1 at 32 weeks gestation presents with fetal hydrops and mirror syndrome. Which pathophysiologic mechanism best explains her severe preeclampsia-like features?", "options": ["Massive fetomaternal hemorrhage causing maternal anemia", "Placental edema releasing soluble fms-like tyrosine kinase-1 (sFlt-1)", "Maternal antibody production against fetal Rh antigens", "Amniotic fluid embolism triggering systemic inflammation", "Mirror syndrome is a misdiagnosis; this is atypical HELLP"], "answer": "B", "answer_index": 1, "explanation": "Mirror syndrome involves placental edema that mechanically compromises uteroplacental perfusion and releases anti-angiogenic factors like sFlt-1, creating a preeclampsia phenotype. Resolution occurs within 48 hours of delivery or fetal therapy that reduces hydrops.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this question about mirror syndrome and its pathophysiology.\n\nMirror syndrome (also called Ballantyne syndrome or triple edema syndrome) is a rare condition where the mother develops edema and preeclampsia-like symptoms that \"mirror\" the hydropic fetus. The key features include:\n- Fetal hydrops (from various causes)\n- Maternal edema\n- Preeclampsia-like features (hypertension, proteinuria)\n\nLet me evaluate each option:\n\nA. Massive fetomaternal hemorrhage causing maternal anemia - This doesn't explain the preeclampsia-like features of mirror syndrome. While fetomaternal hemorrhage can occur, it's not the primary mechanism.\n\nB. Placental edema releasing soluble fms-like tyrosine kinase-1 (sFlt-1) - This is the current leading theory. In mirror syndrome, the edematous/hydropic placenta releases increased amounts of anti-angiogenic factors, particularly sFlt-1. sFlt-1 binds to VEGF and PlGF, causing endothelial dysfunction, which leads to the preeclampsia-like features (hypertension, proteinuria, edema). This is the same pathophysiologic mechanism seen in preeclampsia.\n\nC. Maternal antibody production against fetal Rh antigens - While Rh isoimmunization can cause fetal hydrops, the antibody production itself doesn't explain the maternal preeclampsia-like symptoms.\n\nD. Amniotic fluid embolism triggering systemic inflammation - This is a different obstetric emergency and not related to mirror syndrome.\n\nE. Mirror syndrome is a misdiagnosis; this is atypical HELLP - Mirror syndrome is a recognized clinical entity, not a misdiagnosis.\n\nThe best answer is B, as elevated sFlt-1 from the edematous placenta is the accepted pathophysiologic mechanism explaining the preeclampsia-like features in mirror syndrome.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-006", "question": "A 50-year-old with eosinophilic granulomatosis with polyangiitis undergoes cardiac MRI for suspected myocarditis. Late gadolinium enhancement shows predominant subendocardial involvement with sparing of the epicardium. What is the prognostic implication?", "options": ["Indicates active eosinophilic myocarditis responsive to steroids", "Suggests concomitant coronary artery disease requiring angiography", "Represents fibrotic replacement predicting poor response to immunosuppression", "Typical pattern with no impact on treatment decisions", "Requires endomyocardial biopsy for definitive diagnosis"], "answer": "C", "answer_index": 2, "explanation": "In EGPA, subendocardial LGE pattern indicates chronic fibrotic replacement rather than active inflammation, predicting poor response to immunosuppressive therapy and worse cardiac outcomes. Epicardial LGE correlates with active myocarditis and treatment responsiveness.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Let me analyze this question about cardiac MRI findings in eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome).\n\nIn EGPA, cardiac involvement is a major cause of morbidity and mortality. Cardiac MRI with late gadolinium enhancement (LGE) can help characterize myocardial involvement.\n\nKey considerations for LGE patterns:\n- Subendocardial LGE typically indicates fibrosis/scarring, often associated with ischemic patterns or chronic damage\n- Mid-wall or epicardial LGE is more typical of active inflammatory myocarditis\n- In eosinophilic myocarditis, active inflammation often shows patchy mid-wall or epicardial enhancement\n\nThe question specifically mentions subendocardial involvement with epicardial sparing:\n\n- This pattern in EGPA suggests fibrotic replacement rather than active eosinophilic inflammation\n- Active eosinophilic myocarditis typically shows different patterns (often patchy, mid-myocardial, or subepicardial)\n- Subendocardial fibrosis represents end-stage damage from previous eosinophilic infiltration\n- Fibrotic tissue does not respond to immunosuppressive therapy (steroids/cyclophosphamide)\n- This carries a worse prognosis as the damage is irreversible\n\nOption analysis:\n- A: Incorrect - subendocardial pattern suggests fibrosis, not active inflammation\n- B: While subendocardial can suggest ischemia, in the context of EGPA, this represents eosinophilic damage\n- C: Correct - fibrotic replacement indicates poor response to immunosuppression\n- D: Incorrect - this pattern has significant prognostic implications\n- E: While biopsy can be helpful, the LGE pattern itself has prognostic value\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-007", "question": "An 11-month-old infant presents with a large CNS tumor. Histopathology shows rhabdoid cells with loss of SMARCB1 immunostaining. Molecular profiling reveals a TYR-methylation class. What is the most critical prognostic factor in this subtype?", "options": ["Presence of SMARCB1 deletion alone", "Age <3 years at diagnosis", "MYC oncogene amplification status", "DNA methylation subclassification", "Extent of surgical resection"], "answer": "D", "answer_index": 3, "explanation": "In ATRT, the methylation class (TYR, SHH, MYC) is the dominant prognostic factor, with TYR class having 90% 5-year survival compared to <30% for MYC. SMARCB1 loss is universal, and age is secondary to molecular subclassification in risk stratification.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "Let me analyze this case systematically.\n\nThe presentation describes:\n- 11-month-old infant\n- Large CNS tumor\n- Rhabdoid cells with loss of SMARCB1 immunostaining\n- TYR-methylation class\n\nThis is consistent with Atypical Teratoid/Rhabdoid Tumor (AT/RT), a highly aggressive pediatric CNS tumor characterized by SMARCB1 (INI1) loss.\n\nAT/RT has been classified into three distinct molecular subgroups based on DNA methylation profiling:\n1. AT/RT-TYR (tyrosinase)\n2. AT/RT-SHH (sonic hedgehog)\n3. AT/RT-MYC\n\nThese methylation subgroups have significantly different clinical behaviors and prognoses:\n- AT/RT-TYR typically occurs in infants, often infratentorial, and generally has a better prognosis\n- AT/RT-SHH is often supratentorial\n- AT/RT-MYC tends to have the worst prognosis\n\nThe DNA methylation subclassification has emerged as the most critical prognostic factor in AT/RT, as it:\n1. Defines biologically distinct subgroups\n2. Correlates strongly with clinical outcomes\n3. May guide treatment stratification in clinical trials\n4. Is more predictive than other factors like age alone or extent of resection\n\nWhile age <3 years (option B) and extent of surgical resection (option E) are important prognostic factors in many pediatric brain tumors, the molecular subclassification based on DNA methylation has proven to be the most significant prognostic determinant in AT/RT specifically.\n\nMYC amplification (option C) is relevant but is captured within the methylation subclassification system.\n\nSMARCB1 deletion alone (option A) is the defining feature of AT/RT but doesn't differentiate prognosis within the disease.\n\nThe answer is (D)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-008", "question": "A 76-year-old man with wild-type transthyretin amyloidosis (ATTRwt) has LV wall thickness 16mm and LVEF 45%. Which speckle-tracking echocardiographic finding best distinguishes this from hypertensive heart disease?", "options": ["Global longitudinal strain -8%", "Relative apical sparing ratio >1.5", "Basal sparing pattern", "Circumferential strain >-15%", "Longitudinal strain <10% with basal predominance"], "answer": "B", "answer_index": 1, "explanation": "Relative apical sparing ratio (average apical strain / average basal strain) >1.5 is 93% specific for cardiac amyloidosis, reflecting base-to-apex gradient of amyloid deposition. This pattern is not seen in hypertensive heart disease where strain reduction is homogeneous.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "In cardiac amyloidosis, including wild-type transthyretin amyloidosis (ATTRwt), there is a characteristic pattern on speckle-tracking echocardiography that helps distinguish it from other causes of left ventricular hypertrophy.\n\nThe hallmark finding in cardiac amyloidosis is relative apical sparing of longitudinal strain. This occurs because amyloid deposition tends to be more prominent in the basal and mid-ventricular segments, while the apex is relatively preserved. This creates a distinctive \"cherry on top\" or \"bulls-eye\" pattern on polar maps.\n\nThe relative apical sparing ratio is calculated by dividing the average apical longitudinal strain by the average of basal and mid-ventricular longitudinal strain. A ratio >1.0 indicates apical sparing, and a ratio >1.5 has been shown to have high sensitivity and specificity for distinguishing cardiac amyloidosis from hypertensive heart disease and other causes of LVH.\n\nLet me analyze the options:\n- A. Global longitudinal strain -8%: While reduced GLS is seen in amyloidosis, it's nonspecific and can occur in many conditions\n- B. Relative apical sparing ratio >1.5: This is the characteristic and distinguishing feature of cardiac amyloidosis\n- C. Basal sparing pattern: This is the opposite of what's seen in amyloidosis (amyloidosis shows basal involvement, not sparing)\n- D. Circumferential strain >-15%: Nonspecific finding\n- E. Longitudinal strain <10% with basal predominance: This describes reduced strain that is worse at the base, which is consistent with amyloidosis but the relative apical sparing ratio is the more specific diagnostic criterion\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-009", "question": "A 45-year-old woman with severe verapamil overdose (ingestion 4 hours ago) presents with hypotension (SBP 70mmHg) and hyperglycemia (420mg/dL). You initiate high-dose insulin euglycemia therapy (HIET). What is the target serum glucose range during the first 24 hours?", "options": ["80-110 mg/dL (tight glycemic control)", "110-180 mg/dL (moderate control)", "180-250 mg/dL (permissive hyperglycemia)", "250-350 mg/dL (severe hyperglycemia acceptable)", "No specific target; follow institutional protocol"], "answer": "B", "answer_index": 1, "explanation": "HIET requires maintaining glucose 110-180 mg/dL to prevent hypoglycemia during high-dose insulin infusion (0.5-1 unit/kg/hr) while allowing insulin's inotropic effects. Tighter targets risk hypoglycemia; higher targets may impair insulin's metabolic benefits.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me work through this question about high-dose insulin euglycemia therapy (HIET) for calcium channel blocker overdose.\n\nHIET is used in severe calcium channel blocker (like verapamil) and beta-blocker overdoses. The mechanism involves improving cardiac myocyte metabolism and inotropy through enhanced glucose utilization.\n\nKey considerations for glucose management during HIET:\n\n1. Tight glycemic control (80-110 mg/dL) - This is too aggressive and risks hypoglycemia, which can be dangerous, especially in a critically ill patient receiving high-dose insulin.\n\n2. Moderate control (110-180 mg/dL) - This is the generally recommended target range during HIET. It provides adequate glucose for myocardial metabolism while avoiding both hypoglycemia and severe hyperglycemia.\n\n3. Permissive hyperglycemia (180-250 mg/dL) - While some permissive hyperglycemia may be acceptable initially, this is higher than the recommended target.\n\n4. Severe hyperglycemia (250-350 mg/dL) - This would not be a therapeutic target.\n\n5. No specific target - HIET does have established glucose targets in toxicology guidelines.\n\nDuring HIET, the standard recommendation is to maintain blood glucose between 110-180 mg/dL (or approximately 100-200 mg/dL in some protocols). This moderate range:\n- Prevents dangerous hypoglycemia\n- Ensures adequate substrate for the heart\n- Avoids complications of severe hyperglycemia\n\nThe patient's initial glucose of 420 mg/dL is actually common in CCB overdose due to impaired insulin release from pancreatic beta cells (calcium-dependent process). The HIET will help address both the cardiovascular toxicity and the hyperglycemia.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-010", "question": "A 35-year-old man develops DRESS syndrome 3 weeks after starting phenytoin. He has fever, eosinophilia, atypical lymphocytosis, and transaminitis (AST 450 U/L). HHV-6 PCR becomes positive at day 16 of illness. What is the clinical significance of this virologic finding?", "options": ["Confirms phenytoin as the causative drug", "Indicates need for ganciclovir antiviral therapy", "Predicts higher risk of disease flare and organ damage", "Represents asymptomatic viral reactivation without prognostic value", "Suggests alternative diagnosis of acute HHV-6 infection"], "answer": "C", "answer_index": 2, "explanation": "HHV-6 reactivation at weeks 2-3 in DRESS is pathogenically linked to disease severity, predicting higher risk of relapse, end-organ damage, and prolonged course. It indicates need for more aggressive immunosuppression, not antiviral therapy, as the virus is a marker of immune dysregulation.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Let me analyze this case of DRESS syndrome with HHV-6 reactivation.\n\nDRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome is a severe drug hypersensitivity reaction characterized by:\n- Fever\n- Skin eruption\n- Eosinophilia\n- Atypical lymphocytosis\n- Internal organ involvement (liver, kidney, etc.)\n- Typically occurs 2-8 weeks after drug initiation\n\nHHV-6 reactivation is a well-recognized phenomenon in DRESS syndrome, occurring in approximately 40-60% of cases. Let me evaluate each option:\n\nA. \"Confirms phenytoin as the causative drug\" - HHV-6 reactivation doesn't confirm the causative drug; it's a consequence of the immune dysregulation in DRESS, not a diagnostic marker for the specific drug.\n\nB. \"Indicates need for ganciclovir antiviral therapy\" - Antiviral therapy is not routinely recommended for HHV-6 reactivation in DRESS. Treatment focuses on drug withdrawal and corticosteroids.\n\nC. \"Predicts higher risk of disease flare and organ damage\" - Studies have shown that HHV-6 reactivation in DRESS is associated with more severe disease, prolonged course, higher risk of flares (especially when steroids are tapered), and greater organ involvement including hepatitis.\n\nD. \"Represents asymptomatic viral reactivation without prognostic value\" - This is incorrect; HHV-6 reactivation does have prognostic significance.\n\nE. \"Suggests alternative diagnosis of acute HHV-6 infection\" - Primary HHV-6 infection typically occurs in childhood. In adults with DRESS, this represents reactivation, not primary infection, and DRESS remains the primary diagnosis.\n\nThe clinical significance of HHV-6 reactivation in DRESS is that it correlates with disease severity, prolonged course, and increased risk of flares during steroid tapering.\n\nThe answer is (C)"}]